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Summary: HHV8 shedding in saliva is associated with viral transmission while viral 
detection in blood is associated with disease pathogensis. Our data shows that children may 
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Detectable KSHV DNA in blood and increased antibody titres may indicate KSHV 
reactivation, while transmission of KSHV occurs via viral shedding in saliva.  
 
Methods 
We investigated risk factors for KSHV DNA detection by real-time PCR, in blood and viral 
shedding in saliva, in 878 people aged 3 to 89 years of both sexes in a rural Ugandan 
population cohort. Helminths were detected using microscopy and malaria parasitaemia was 
identified using rapid diagnostic tests. Regression modelling was used for statistical 
analysis. 
 
Results and discussion 
KSHV viral load in blood did not correlate with viral load in saliva, suggesting separate 
immunological control within each compartment. The proportion of individuals with 
detectable virus in blood was 23% among children aged 3-5 years , 22% among 6-12 years 
old, thereafter reducing with increasing age. The proportion of individuals with detectable 
virus in saliva increased from 30% in 3-5 year old children to 45% in those aged 6-12 and 
decreasing subsequently with increasing age. Overall, 29% of males shed in saliva 
compared to 19% of females  (p = 0.008). Together, these data suggest that young males 
may be responsible for much of the onward transmission of KSHV. Individuals with a current 
malaria infection had higher levels of viral DNA in blood (p = 0.031) compared to malaria 
uninfected individuals. This suggests that malaria may lead to KSHV reactivation, thereby 
increasing transmission and pathogenicity of the virus.  
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Kaposi's sarcoma-associated herpesvirus (KSHV) causes Kaposi’s sarcoma (KS), 
multicentric Castleman disease (MCD) and primary effusion lymphoma (PEL) (1-6). 
Prevalence of KSHV and incidence of KS both vary geographically, (7-9) and are endemic in 
sub-Saharan Africa (10, 11) . 
 
Salivary exchange is the main route of transmission of KSHV, normally occurring in early 
childhood and increasing with age (12-15). In a rural population cohort in Uganda (the 
General Population Cohort – GPC), for instance, we have reported KSHV infections in 
children as young as one year (11, 16). In addition to viral shedding in saliva, viral DNA 
detection in blood and increased antibody titres to lytic antigens are markers of frequent 
KSHV reactivation (13). KSHV-associated oncogenesis and progression of dieases, as well 
as virus transmission, are all thought to be related to virus reactivation (17).  
 
Viral DNA detection in blood has been associated with KS disease risk and progression (18-
21). Additionally, treatment of AIDS-KS patients with cART has been shown to reduce KSHV 
load in blood to undetectable levels (18, 22). Determinants of KSHV DNA detection in blood 
among KSHV seropositive people in the general population is not well understood. Viral load 
in plasma and PBMCs has been reported mainly in high-risk groups such as HIV infected 
individuals and patients with KSHV related diseases (18, 23-27). A few studies have 
reported KSHV viral load in blood donors (adults) in non-endemic areas (28-30) and a study 
reported plasma viral load in a population-based HIV survey in an endemic area (31).  
 
Environmental factors may contribute to high KSHV transmission in endemic areas. We 
have previously shown that KSHV seroprevalence is associated with malaria parasitaemia 
(16), higher malaria antibody titres (32) and helminth infections (33, 34). We and others have 
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36), but no study has investigated KSHV viral load in both blood and saliva in the same 
individuals within a population- based study in a KSHV endemic area. 
 
This study investigated KSHV viral DNA detection in PBMCs and saliva in KSHV 
seropositive individuals aged 3 to 89 years from the General Population Cohort (GPC) – a 
longstanding cohort in rural south-western Uganda. We also determined the risk factors 
associated with viral DNA detection and levels in PBMCs and in saliva, and the relationship 
between viral DNA detection in PBMCs and saliva and KSHV antibody levels in plasma.  
 
Methods 
Study population and ethical approvals 
This work was carried out within the General Population Cohort (GPC). The GPC is a 
community-based cohort of 22,000 people in 25 adjacent villages in south-western Uganda. 
It was established in 1989 to carry out HIV research; participants from the GPC have been 
followed ever since. Between July 2017 and November 2017, we nested a cross-sectional 
study within the GPC enrolling 975 KSHV seropositive (tested previously (32)), HIV negative 
individuals aged three to eighty-nine years. Participants were selected randomly after 
stratification for age, sex and household. Blood, stool and saliva samples were collected 
from these individuals. Peripheral blood mononuclear cells (PBMCs) and plasma were 
obtained from blood for immunological and virological analyses. Stool samples were used 
for helminth diagnosis while saliva was used for KSHV viral DNA detection and 
quantification. Socio-demographic data were collected using standard questionnaires. This 
study was approved by the UVRI-Research and Ethics Committee (REC) (reference 
number: GC/127/16/09/566), the Uganda National Council for Science and Technology 
(UNCST) (reference number: HS2123) and LSHTM Ethics Committee (reference number: 
11881). Written informed consent was obtained from all adults aged 18 years and above. 
Parents or guardians consented for children below 18 years, additionally, children aged 8-17 
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Laboratory procedures   
KSHV DNA was quantified in PBMCs and saliva from 878 KSHV seropositive individuals. A 
pellet of about two million PBMCs and saliva pellets were processed for DNA extraction. 
Study participants were instructed to rinse with 5mL of Listerine mouthwash, empting it, as 
well as saliva in a falcon tube. Aliquots (of 1mL each) of saliva were spun at 13,000rcf for 10 
minutes to form saliva pellets. Thereafter the supernatant was removed and the saliva pellet 
stored at -80oC. Genomic DNA was extracted from PBMCs and saliva pellets using a 
QIAamp blood kit (Qiagen, Valencia, CA), following the manufacturer's instructions. KSHV 
DNA was quantified using real-time PCR, following procedures previously reported (13, 37, 
38). KSHV DNA was detected using primers and a probe specific to the K6 gene region (39). 
Additionally, the number of cellular equivalents in PBMCs were determined using a 
quantitative assay specific to human endogenous retrovirus 3 (ERV-3) (39), which is present 
in two copies per genomic cell. Raw copies were reported for saliva KSHV DNA. Samples 
were amplified in triplicate; the samples that were positive in one or two reactions in the 
KSHV K6 assay were designated as qualitative positives. The sensititivity of the K6 assay is 
3 copies.  
 
Using an in house Luminex assay and ELISA, previously reported (40-42), plasma samples 
were tested for IgG antibody levels to the KSHV K8.1 (lytic) and ORF73 (latent) antigens. 
The ELISA was used to confirm serostatus while the Luminex assay was used to determine 
antibody levels, due to its wider dynamic range. Malaria parasitemia was diagnosed using 
rapid diagnostic tests (RDT) (ONE STEP Malaria HRP-II (P.f) and pLDH (Pan) Antigen 
Rapid Test). A single stool sample was provided by each participant. This was analysed for 
helminths (Schistosoma mansoni, Ascaris lumbricoides, Tichuris trichiura, Trichostrongylus 
spp and hookworm) using the Kato Katz microscopy method following the manufacturer’s 
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Statistical analysis was carried out using STATA version 13 (Statacorp, College Station, 
Texas USA). Graphs were drawn using STATA and GraphPad Prism version 6. Qualitative 
positive samples were given a constant value of 0.04 for saliva and 0.5 for PBMCs, which 
were below the values of the lowest qualified samples for quantitative analysis. Viral load 
levels were log10 transformed. First, risk factors associated with viral DNA detection (as a 
categorical outcome variable) in saliva and blood, separately, were obtained using  logistic 
regression modelling.  Thereafter, risk factors associated with increasing levels of viral DNA 
(as a continuous outcome variable) in saliva and in blood, separately, were determined 




Study participants’ characteristics 
We tested 878 individuals for KSHV viral DNA; 49% (410/834) were males, while 3% 
(27/840), 11% (95/840), 13% (110/840), 8% (67/840), 17% (139/840), 14% (121/840), 14% 
(118/840), 9% (74/840) and 11% (89/840) were aged 3-5, 6-12, 13-18, 19-25, 26-35, 36-45, 
46-55, 56-65 and 66-89 years respectively (Table 1). The proportion of individuals with 
malaria parasitaemia was 4% (34/834) overall and 11% (13/120) among children 3-12 years. 
Previously we have reported an annual malaria prevalence of 18% in the same population 
(16). The lower prevalence of malaria infection in this study might be attributed to sample 
collection during the dry season. The prevalence of helminths was as follows: Hookworm 
was the most prevalent at 15% (104/686), followed by Schistosoma mansoni and Ascaris 
lumbricoides at 1%  (8/686) each and Trichuris trichiura at 0.1% (1/686). We may have 
slightly underestimated the true prevalence of helminths,  because a single, rather than triple 
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Blood and saliva KSHV DNA detection and levels of viral DNA 
We did not observe a correlation between KSHV DNA copy numbers in PBMCs and DNA 
copy numbers in saliva (Figure 1). The proportion of individuals with detectable viral DNA in 
saliva was higher than the proportion of people with the detectable viral DNA in PBMCs 
(Figure 2a and 2b). Children had the highest proportion of detectable viral DNA in PBMCs 
(Figure 2a) and in saliva (Figure 2b), decreasing with increasing age in adults. The trend 
was similar for females and males, with males having higher proportions of detectable viral 
DNA in saliva.  
 
Associations between risk factors and KSHV DNA in PBMCs 
The proportion of individuals with detectable viral DNA in PBMCs decreased with increasing 
age; this trend was significant even after adjusting for sex and parasite infections (Table 2). 
Individuals infected with malaria parasites had higher levels of KSHV DNA in blood 
compared to malaria uninfected individuals (adjusted regression coefficient 0.79 (0.07,1.50), 
p=0.031) (Table 3). We observe no statistically significant associations with other measured 
risk factors including age, sex, hookworm and S. mansoni infections (Table 3).  
 
Associations between risk factors and KSHV DNA in saliva 
Overall, males had a higher risk of shedding viral DNA compared to females; adjusted Odds 
Ratio 1.63 (1.14, 2.34), p=0.008 (Table 4). Similar to PBMCs, the proportion of shedders in 
saliva diminished with increasing age, even after adjusting for sex and parasite infections 
p=0.0001 (Table 4). Additionally, compared to females, males had higher levels of KSHV 
DNA in saliva (adjusted regression coefficient 0.46 (0.05,0.87), p=0.027) (Table 5).  
 
KSHV DNA detection and antibody levels 
Individuals with detectable viral DNA in PBMCs (Supplementary Figure 1a) and in saliva 
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(13). There was no difference in IgG antibodies to ORF73 antigen between individuals with 
or without detectable viral DNA in the blood (Supplementary Figure 1c) or in saliva 
(Supplementary Figure 1d). 
 
Discussion 
This is the first population-based study to report on presence and levels of KSHV viral DNA 
in blood and saliva in apparently healthy people across the lifecourse. The proportion of 
individuals with detectable viral DNA in saliva was higher than the proportion of individuals 
with detectable viral DNA in blood, consistent with previous reports (22, 45-47). We have 
previously reported KSHV and EBV DNA shedding in saliva of children and their mothers in 
Uganda and noted that EBV DNA was shed more frequently and at higher levels than KSHV 
(38).  
 
In this study, we observed no correlation between levels of KSHV DNA in blood and in 
saliva. Detection of KSHV DNA in blood and in saliva may reflect reactivation of the virus or 
an initial infection that manifests with lytic replication. Viral shedding in saliva leads to 
transmission of the virus (13), while viral load in blood has been implicated in disease risk 
and progression (18, 23). The lack of a correlation between blood and saliva viral DNA 
suggests that the mechanisms for reactivation of the virus in blood and in saliva may be 
different. This may imply that distinct immune control measures are required to prevent viral 
reactivation in the different compartments. For insistence, IgA production in saliva may be 
important for viral control in oral fluids, while T and NK cell responses may play a more 
pivotal role in the control of viral reactivation in peripheral blood. Alternatively environmental 
factors such as plant derrivates that have been shown to reactivate KSHV in vitro (48) may 
play a role in viral reactivation in oral fluids if chewed. Studies of immune correlates of KSHV 
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The proportion of KSHV DNA detected in blood and saliva was highest in children, 
compared to adults. Previous studies have reported a high risk of KSHV seropositivity in 
children born to KSHV seropositive mothers (13, 35, 49). However, seropositivity in children 
whose mothers were seronegative has also been reported (49, 50). Our current study 
suggests that siblings or playmates may also be a major source of transmission to 
uninfected children.  
 
High viral load among children could be associated with co-infections that are very prevalent 
in childhood such as malaria; we also observed the highest prevalence of malaria 
parasitaemia in the same age group. We showed that participants with malaria parasitaemia 
have higher levels of KSHV DNA in blood compared to those uninfected with malaria. This is 
the first study to relate malaria parasitaemia directly with KSHV load in blood. We have 
previously reported associations between malaria (parasitaemia and antibodies) and KSHV 
seroprevalence (16, 32-34). Results from the current study support a potential role of 
malaria in KSHV pathogenesis. The mechanisms for the association between malaria and 
KSHV viral load could include immunomodulation and dysfunction associated with repeated 
malaria infections (51, 52).  
 
In the present study, males (both men and boys) were more likely to shed KSHV DNA in 
saliva and had higher levels of viral DNA compared to females. This is consistent with 
previous studies by us and others (31, 36, 38). Sex differences in immune control of KSHV 
infection might contribute to the higher risk of KS in men (53, 54). These findings warrant 
further study. 
 
We have previously reported that high KSHV K8.1 antibody titres are associated with and 
predictive of KS risk (55). In the current study, we have observed that people with detectable 
viral DNA in both blood and saliva have higher IgG antibody levels for K8.1 but not ORF73, 
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previous hypothesis (55) that increased lytic antibody levels reflect more frequent KSHV 
reactivation. 
 
In summary, our data are consistent with high rates of KSHV transmission in rural Uganda. 
This might be partly attributed to parasite co-infections such as malaria which interfere with 
immune control, or make uninfected children susceptible to infections. Studies investigating 
the mechanism through which malaria affects KSHV are required. Additionally, 
characterisation of protective immune responses to KSHV is needed to inform vaccine 








/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of H
ygiene & Tropical M





We acknowledge the study participants from Kyamulibwa, Kalungu district. We recognise 
the General Population Cohort (GPC) and Clinical Diagnostic Laboratory services (CDLS) 
teams at MRC/UVRI who participated in data and sample collection. 
 
Disclaimer 
The content of this publication does not necessarily reflect the views or policies of the 
Department of Health and Human Services, nor does mention of trade names, commercial 
products, or organizations imply endorsement by the U.S. Government. 
 
Funding 
This research was partially funded by the African Partnership for Chronic Disease Research 
(APCDR), University of Cambridge, United Kingdom. It has been funded in part with federal 
funds from the National Cancer Institute, National Institutes of Health, under Contract 
Number. HHSN261200800001E. This research was supported in part by the Intramural 
Research Program of the NIH, National Cancer Institute. It also received support from the 
Makerere University/UVRI Centre of Excellence for Infection and Immunity Research and 
Training (MUII-plus).  MUII-plus is supported through the DELTAS Africa Initiative (Grant no. 
107743). The DELTAS Africa Initiative is an independent funding scheme of the African 
Academy of Sciences (AAS), Alliance for Accelerating Excellence in Science in Africa 
(AESA), and supported by the New Partnership for Africa's Development Planning and 
Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (Grant 
no.107743) and the UK Government. The MRC/UVRI and LSHTM Uganda Research Unit is 
jointly funded by the UK Medical Research Council (MRC) and the UK Department for 
International Development (DFID) under the MRC/DFID Concordat agreement and is also 
part of the EDCTP2 programme supported by the European Union. 






/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of H
ygiene & Tropical M





1. Schulz TF. Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8). The 
Journal of general virology. 1998;79 ( Pt 7):1573-91. 
2. Sunil M, Reid E, Lechowicz MJ. Update on HHV-8-Associated Malignancies. Current 
infectious disease reports. 2010;12(2):147-54. 
3. Chang Y, Moore PS. Kaposi's Sarcoma (KS)-associated herpesvirus and its role in KS. 
Infectious agents and disease. 1996;5(4):215-22. 
4. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated 
herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. The New 
England journal of medicine. 1995;332(18):1186-91. 
5. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, et al. 
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's 
disease. Blood. 1995;86(4):1276-80. 
6. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification 
of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science (New York, 
NY). 1994;266(5192):1865-9. 
7. Rohner E, Wyss N, Trelle S, Mbulaiteye SM, Egger M, Novak U, et al. HHV-8 
seroprevalence: a global view. Systematic reviews. 2014;3:11. 
8. Weiss RA, Whitby D, Talbot S, Kellam P, Boshoff C. Human herpesvirus type 8 and 
Kaposi's sarcoma. Journal of the National Cancer Institute Monographs. 1998(23):51-4. 
9. Uldrick TS, Whitby D. Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, 
and treatment of Kaposi Sarcoma. Cancer letters. 2011;305(2):150-62. 
10. Dedicoat M, Newton R. Review of the distribution of Kaposi's sarcoma-associated 
herpesvirus (KSHV) in Africa in relation to the incidence of Kaposi's sarcoma. British journal 
of cancer. 2003;88(1):1-3. 
11. Newton R, Labo N, Wakeham K, Miley W, Asiki G, Johnston WT, et al. Kaposi 
Sarcoma-Associated Herpesvirus in a Rural Ugandan Cohort, 1992-2008. The Journal of 
infectious diseases. 2018;217(2):263-9. 
12. Kaposi's sarcoma herpesvirus/human herpesvirus 8. IARC monographs on the 
evaluation of carcinogenic risks to humans / World Health Organization, International 
Agency for Research on Cancer. 1997;70:375-492. 
13. Dedicoat M, Newton R, Alkharsah KR, Sheldon J, Szabados I, Ndlovu B, et al. Mother-
to-child transmission of human herpesvirus-8 in South Africa. The Journal of infectious 
diseases. 2004;190(6):1068-75. 
14. Minhas V, Crabtree KL, Chao A, M'Soka T J, Kankasa C, Bulterys M, et al. Early 
childhood infection by human herpesvirus 8 in Zambia and the role of human 
immunodeficiency virus type 1 coinfection in a highly endemic area. American journal of 
epidemiology. 2008;168(3):311-20. 
15. Whitby D, Luppi M, Sabin C, Barozzi P, Di Biase AR, Balli F, et al. Detection of 
antibodies to human herpesvirus 8 in Italian children: evidence for horizontal transmission. 
British journal of cancer. 2000;82(3):702-4. 
16. Nalwoga A, Cose S, Nash S, Miley W, Asiki G, Kusemererwa S, et al. Relationship 
between Anaemia, Malaria Co-infection and Kaposi Sarcoma-associated Herpesvirus (KSHV) 







/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of H
ygiene & Tropical M




17. Aneja KK, Yuan Y. Reactivation and Lytic Replication of Kaposi's Sarcoma-Associated 
Herpesvirus: An Update. Frontiers in microbiology. 2017;8:613. 
18. Broccolo F, Tassan Din C, Vigano MG, Rutigliano T, Esposito S, Lusso P, et al. HHV-8 
DNA replication correlates with the clinical status in AIDS-related Kaposi's sarcoma. Journal 
of clinical virology : the official publication of the Pan American Society for Clinical Virology. 
2016;78:47-52. 
19. Engels EA, Biggar RJ, Marshall VA, Walters MA, Gamache CJ, Whitby D, et al. 
Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-
associated Kaposi's sarcoma. Aids. 2003;17(12):1847-51. 
20. Jary A, Leducq V, Palich R, Gothland A, Descamps D, Joly V, et al. Usefulness of 
Kaposi's Sarcoma-Associated Herpesvirus (KSHV) DNA Viral Load in Whole Blood for 
Diagnosis and Monitoring of KSHV-Associated Diseases. Journal of clinical microbiology. 
2018;56(6). 
21. Pellet C, Chevret S, Frances C, Euvrard S, Hurault M, Legendre C, et al. Prognostic 
value of quantitative Kaposi sarcoma--associated herpesvirus load in posttransplantation 
Kaposi sarcoma. The Journal of infectious diseases. 2002;186(1):110-3. 
22. Tedeschi R, Enbom M, Bidoli E, Linde A, De Paoli P, Dillner J. Viral load of human 
herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with 
Kaposi's sarcoma. Journal of clinical microbiology. 2001;39(12):4269-73. 
23. Borok M, Fiorillo S, Gudza I, Putnam B, Ndemera B, White IE, et al. Evaluation of 
plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral 
therapy for AIDS-related Kaposi sarcoma in Zimbabwe. Clinical infectious diseases : an 
official publication of the Infectious Diseases Society of America. 2010;51(3):342-9. 
24. Campbell TB, Borok M, White IE, Gudza I, Ndemera B, Taziwa A, et al. Relationship of 
Kaposi sarcoma (KS)-associated herpesvirus viremia and KS disease in Zimbabwe. Clinical 
infectious diseases : an official publication of the Infectious Diseases Society of America. 
2003;36(9):1144-51. 
25. Laney AS, Cannon MJ, Jaffe HW, Offermann MK, Ou CY, Radford KW, et al. Human 
herpesvirus 8 presence and viral load are associated with the progression of AIDS-associated 
Kaposi's sarcoma. Aids. 2007;21(12):1541-5. 
26. Nsubuga MM, Biggar RJ, Combs S, Marshall V, Mbisa G, Kambugu F, et al. Human 
herpesvirus 8 load and progression of AIDS-related Kaposi sarcoma lesions. Cancer letters. 
2008;263(2):182-8. 
27. Polstra AM, Cornelissen M, Goudsmit J, van der Kuyl AC. Retrospective, longitudinal 
analysis of serum human herpesvirus-8 viral DNA load in AIDS-related Kaposi's sarcoma 
patients before and after diagnosis. Journal of medical virology. 2004;74(3):390-6. 
28. Hulaniuk ML, Torres O, Bartoli S, Fortuny L, Burgos Pratx L, Nunez F, et al. Increased 
prevalence of human herpesvirus type 8 (HHV-8) genome among blood donors from North-
Western Argentina. Journal of medical virology. 2017;89(3):518-27. 
29. Enbom M, Urassa W, Massambu C, Thorstensson R, Mhalu F, Linde A. Detection of 
human herpesvirus 8 DNA in serum from blood donors with HHV-8 antibodies indicates 
possible bloodborne virus transmission. Journal of medical virology. 2002;68(2):264-7. 
30. Hudnall SD, Chen T, Rady P, Tyring S, Allison P. Human herpesvirus 8 seroprevalence 
and viral load in healthy adult blood donors. Transfusion. 2003;43(1):85-90. 
31. Shebl FM, Emmanuel B, Bunts L, Biryahwaho B, Kiruthu C, Huang ML, et al. 
Population-based assessment of kaposi sarcoma-associated herpesvirus DNA in plasma 






/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of H
ygiene & Tropical M




32. Nalwoga A, Cose S, Wakeham K, Miley W, Ndibazza J, Drakeley C, et al. Association 
between malaria exposure and Kaposi's sarcoma-associated herpes virus seropositivity in 
Uganda. Tropical medicine & international health : TM & IH. 2015;20(5):665-72. 
33. Wakeham K, Webb EL, Sebina I, Muhangi L, Miley W, Johnson WT, et al. Parasite 
infection is associated with Kaposi's sarcoma associated herpesvirus (KSHV) in Ugandan 
women. Infectious agents and cancer. 2011;6(1):15. 
34. Wakeham K, Webb EL, Sebina I, Nalwoga A, Muhangi L, Miley W, et al. Risk factors 
for seropositivity to Kaposi sarcoma-associated herpesvirus among children in Uganda. J 
Acquir Immune Defic Syndr. 2013;63(2):228-33. 
35. Newton R, Labo N, Wakeham K, Marshall V, Roshan R, Nalwoga A, et al. 
Determinants of gamma-herpesvirus shedding in saliva among Ugandan children and their 
mothers. The Journal of infectious diseases. 2018. 
36. Bender Ignacio RA, Goldman JD, Magaret AS, Selke S, Huang ML, Gantt S, et al. 
Patterns of human herpesvirus-8 oral shedding among diverse cohorts of human 
herpesvirus-8 seropositive persons. Infectious agents and cancer. 2016;11:7. 
37. de Sanjose S, Marshall V, Sola J, Palacio V, Almirall R, Goedert JJ, et al. Prevalence of 
Kaposi's sarcoma-associated herpesvirus infection in sex workers and women from the 
general population in Spain. International journal of cancer Journal international du cancer. 
2002;98(1):155-8. 
38. Newton R, Labo N, Wakeham K, Marshall V, Roshan R, Nalwoga A, et al. 
Determinants of Gammaherpesvirus Shedding in Saliva Among Ugandan Children and Their 
Mothers. The Journal of infectious diseases. 2018;218(6):892-900. 
39. Yuan CC, Miley W, Waters D. A quantification of human cells using an ERV-3 real 
time PCR assay. Journal of virological methods. 2001;91(2):109-17. 
40. Labo N, Miley W, Marshall V, Gillette W, Esposito D, Bess M, et al. Heterogeneity and 
breadth of host antibody response to KSHV infection demonstrated by systematic analysis 
of the KSHV proteome. PLoS pathogens. 2014;10(3):e1004046. 
41. Nalwoga A, Miley W, Labo N, Elliott A, Cose S, Whitby D, et al. Age of Infection with 
Kaposi Sarcoma Associated Herpesvirus and Subsequent Antibody Values Among Children in 
Uganda. The Pediatric infectious disease journal. 2018. 
42. Mbisa GL, Miley W, Gamache CJ, Gillette WK, Esposito D, Hopkins R, et al. Detection 
of antibodies to Kaposi's sarcoma-associated herpesvirus: a new approach using K8.1 ELISA 
and a newly developed recombinant LANA ELISA. Journal of immunological methods. 
2010;356(1-2):39-46. 
43. Bukusuba JW, Hughes P, Kizza M, Muhangi L, Muwanga M, Whitworth JA, et al. 
Screening for intestinal helminth infection in a semi-urban cohort of pregnant women in 
Uganda. Tropical doctor. 2004;34(1):27-8. 
44. Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool thick-smear 
technique in Schistosomiasis mansoni. Revista do Instituto de Medicina Tropical de Sao 
Paulo. 1972;14(6):397-400. 
45. Blackbourn DJ, Lennette ET, Ambroziak J, Mourich DV, Levy JA. Human herpesvirus 8 
detection in nasal secretions and saliva. The Journal of infectious diseases. 1998;177(1):213-
6. 
46. Pauk J, Huang ML, Brodie SJ, Wald A, Koelle DM, Schacker T, et al. Mucosal shedding 







/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of H
ygiene & Tropical M




47. Triantos D, Horefti E, Paximadi E, Kyriakopoulou Z, Karakassiliotis G, Papanastasiou K, 
et al. Presence of human herpes virus-8 in saliva and non-lesional oral mucosa in HIV-
infected and oncologic immunocompromised patients. Oral microbiology and immunology. 
2004;19(3):201-4. 
48. Whitby D, Marshall VA, Bagni RK, Miley WJ, McCloud TG, Hines-Boykin R, et al. 
Reactivation of Kaposi's sarcoma-associated herpesvirus by natural products from Kaposi's 
sarcoma endemic regions. International journal of cancer Journal international du cancer. 
2007;120(2):321-8. 
49. Borges JD, Souza VA, Giambartolomei C, Dudbridge F, Freire WS, Gregorio SA, et al. 
Transmission of human herpesvirus type 8 infection within families in american indigenous 
populations from the Brazilian Amazon. The Journal of infectious diseases. 
2012;205(12):1869-76. 
50. Olp LN, Shea DM, White MK, Gondwe C, Kankasa C, Wood C. Early childhood 
infection of Kaposi's sarcoma-associated herpesvirus in Zambian households: a molecular 
analysis. International journal of cancer Journal international du cancer. 2013;132(5):1182-
90. 
51. Kijogi C, Kimura D, Bao LQ, Nakamura R, Chadeka EA, Cheruiyot NB, et al. 
Modulation of immune responses by Plasmodium falciparum infection in asymptomatic 
children living in the endemic region of Mbita, western Kenya. Parasitology international. 
2018;67(3):284-93. 
52. Loughland JR, Woodberry T, Boyle MJ, Tipping PE, Piera KA, Amante FH, et al. 
Plasmodium falciparum activates CD16+ dendritic cells to produce TNF and IL-10 in 
subpatent malaria. The Journal of infectious diseases. 2018. 
53. Biryahwaho B, Dollard SC, Pfeiffer RM, Shebl FM, Munuo S, Amin MM, et al. Sex and 
geographic patterns of human herpesvirus 8 infection in a nationally representative 
population-based sample in Uganda. The Journal of infectious diseases. 2010;202(9):1347-
53. 
54. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: 
a cancer journal for clinicians. 2011;61(2):69-90. 
55. Wakeham K, Johnston WT, Nalwoga A, Webb EL, Mayanja BN, Miley W, et al. Trends 
in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-
associated Kaposi's sarcoma: a nested case-control study. International journal of cancer 








/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of H
ygiene & Tropical M





Figure 1: KSHV viral load in saliva and in peripheral blood mononuclear cells (PBMCs). 
KSHV viral loads were measured using real time PCR.  
Figure 2: Proportion of individuals with detectable KSHV in peripheral blood mononuclear 
cells (PBMCs) (A) and saliva (B). KSHV viral loads were measured using real time PCR. 
Supplementary Figure 1: IgG antibody levels to K8.1 (A & B) and ORF73 ( C& D) protein 
among individuals with and without detectable KSHV in blood (A & C) and in saliva (B & D). 
Antibodies were measured using Luminex assay. These antibodies were log10 transformed. 
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Table 1: General characteristics and parasite infections status among participants tested for 
KSHV viral DNA 
 
Sex, males 49% (410/834) 




























Schistosoma mansoni infection status 1% (7/686) 
Hookworm infection status 15% (104/686) 
Ascaria lumbricoides infection status 1% (8/686) 
Trichuris trichiura infection status 0.2% (1/685) 
Malaria parasitaemia was determined using rapid diagnostic tests (RDTs). Helminth status 
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Table 2: Risk factors for the presence of detectable KSHV DNA in blood (categorically) 
 % detectable viral 
DNA in blood 















0.59 (0.33, 1.08) 
0.24 (0.13, 0.45) 








0.63 (0.33, 1.17) 
0.29 (0.15, 0.57) 




















































































a OR: odds ratio, b adjusted for age, sex, malaria parasitaemia, S. mansoni and hookworm 
infection status. Logistic regression was used for statistical analysis. Malaria parasitaemia 
was determined using rapid diagnostic tests (RDTs). Helminth status was determined from a 
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Table 3: Risk factors associated with increasing  levels of KSHV DNA in blood (continuously) 










-0.39 (-0.86, 0.07) 
0.19 (-0.31, 0.69) 








-0.35 (-0.84, 0.15) 
0.26 (-0.30, 0.83) 







































































a Coef: linear regression coefficient, b adjusted for age, sex, malaria parasitaemia, S. 
mansoni and hookworm infection status. Linear regression modelling was performed on 
log10 transformed KSHV DNA levels for statistical analysis. Malaria parasitaemia was 
determined using rapid diagnostic tests (RDTs). Helminth status was determined from a 
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Table 4: Risk factors for the presence of detectable KSHV DNA in saliva (categorically) 
 % detectable viral 
DNA in saliva 















0.64 (0.40, 1.40) 
0.31 (0.19, 0.49) 








0.61 (0.37, 1.02) 
0.38 (0.24, 0.63) 




















































































a OR: odds ratio, b adjusted for age, sex, malaria parasitaemia, S. mansoni and hookworm 
infection status. Logistic regression was used for statistical analysis. Malaria parasitaemia 
was determined using rapid diagnostic tests (RDTs). Helminth status was determined from a 
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Table 5: Risk factors associated with levels of KSHV DNA in saliva (continuously)  








-0.50 (-1.02, 0.21) 
-0.31 (-0.82, 0.21) 








-0.61 (-0.13, -0.09) 
-0.26 (-0.80, 0.28) 







































































a Coef: linear regression coefficient, b adjusted for age, sex, malaria parasitaemia, S. 
mansoni and hookworm infection status. Linear regression modelling was performed on 
log10 transformed KSHV DNA levels for statistical analysis. Malaria parasitaemia was 
determined using rapid diagnostic tests (RDTs). Helminth status was determined from a 
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